Inhibrx (INBX) Competitors $13.16 +0.09 (+0.69%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$13.16 0.00 (0.00%) As of 05/21/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. TRVI, PHAR, DAWN, DNTH, IOVA, ABUS, AKBA, ZYBT, EOLS, and XNCRShould you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Trevi Therapeutics (TRVI), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Akebia Therapeutics (AKBA), Zhengye Biotechnology (ZYBT), Evolus (EOLS), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. Inhibrx vs. Trevi Therapeutics Pharming Group Day One Biopharmaceuticals Dianthus Therapeutics Iovance Biotherapeutics Arbutus Biopharma Akebia Therapeutics Zhengye Biotechnology Evolus Xencor Inhibrx (NASDAQ:INBX) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership. Do analysts prefer INBX or TRVI? Trevi Therapeutics has a consensus target price of $17.56, indicating a potential upside of 184.18%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.30 Does the MarketBeat Community prefer INBX or TRVI? Trevi Therapeutics received 76 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 68.15% of users gave Trevi Therapeutics an outperform vote while only 57.41% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformInhibrxOutperform Votes3157.41% Underperform Votes2342.59% Trevi TherapeuticsOutperform Votes10768.15% Underperform Votes5031.85% Is INBX or TRVI more profitable? Trevi Therapeutics' return on equity of -63.31% beat Inhibrx's return on equity.Company Net Margins Return on Equity Return on Assets InhibrxN/A -113.74% -80.56% Trevi Therapeutics N/A -63.31%-57.06% Does the media favor INBX or TRVI? In the previous week, Inhibrx and Inhibrx both had 6 articles in the media. Trevi Therapeutics' average media sentiment score of 1.16 beat Inhibrx's score of 0.35 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, INBX or TRVI? Trevi Therapeutics has lower revenue, but higher earnings than Inhibrx. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx$200K952.52-$154.96M$116.750.11Trevi TherapeuticsN/AN/A-$29.07M-$0.45-13.73 Do institutionals & insiders hold more shares of INBX or TRVI? 82.5% of Inhibrx shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 17.1% of Inhibrx shares are owned by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryTrevi Therapeutics beats Inhibrx on 12 of the 15 factors compared between the two stocks. Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$190.50M$2.93B$5.37B$8.39BDividend YieldN/A1.72%5.22%4.10%P/E Ratio0.1130.5026.8419.71Price / Sales952.52400.15392.34117.39Price / CashN/A168.6838.2534.62Price / BookN/A3.286.794.50Net Income-$154.96M-$72.17M$3.23B$248.18M7 Day Performance9.48%2.96%1.53%0.20%1 Month Performance10.87%3.25%10.05%12.37%1 Year Performance-61.76%-28.29%16.71%7.04% Inhibrx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx1.8939 of 5 stars$13.16+0.7%N/A-61.6%$190.50M$200,000.000.11166TRVITrevi Therapeutics3.6014 of 5 stars$6.70+1.5%$17.56+162.1%+126.4%$669.28MN/A-15.2320Positive NewsAnalyst ForecastPHARPharming Group1.5265 of 5 stars$9.81-2.2%$30.00+206.0%+11.2%$667.04M$297.20M-37.71280Negative NewsGap UpDAWNDay One Biopharmaceuticals2.9033 of 5 stars$6.58+2.0%$30.57+364.6%-57.5%$666.96M$161.92M-6.3960Gap UpDNTHDianthus Therapeutics1.2697 of 5 stars$20.08+2.5%$54.33+170.6%-23.7%$645.09M$6.24M-8.0380IOVAIovance Biotherapeutics4.4368 of 5 stars$1.93+10.3%$14.80+666.8%-83.0%$644.49M$212.68M-1.30500Trending NewsGap DownHigh Trading VolumeABUSArbutus Biopharma1.8646 of 5 stars$3.35+3.7%$5.50+64.2%-1.2%$641.46M$6.17M-7.7990Earnings ReportGap UpAKBAAkebia Therapeutics4.225 of 5 stars$2.43-4.7%$6.63+172.6%+148.7%$636.14M$160.18M-10.56430High Trading VolumeZYBTZhengye BiotechnologyN/A$13.43+30.3%N/AN/A$633.44M$189.75M0.00278Gap DownEOLSEvolus3.5772 of 5 stars$9.98+1.8%$23.75+138.0%-27.1%$631.87M$266.27M-10.97170Gap UpHigh Trading VolumeXNCRXencor3.7047 of 5 stars$8.77+5.3%$29.50+236.4%-68.4%$624.00M$110.49M-2.74280 Related Companies and Tools Related Companies Trevi Therapeutics Alternatives Pharming Group Alternatives Day One Biopharmaceuticals Alternatives Dianthus Therapeutics Alternatives Iovance Biotherapeutics Alternatives Arbutus Biopharma Alternatives Akebia Therapeutics Alternatives Zhengye Biotechnology Alternatives Evolus Alternatives Xencor Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INBX Stock Free INBX Stock Alerts